Breaking News
Top News
-
Gold Gives Back Late Gains After War Rhetoric Shift and Strong Jobs Data
-
Buying a Home Just Cleaned Out Your Savings Account. Here’s What an Expert Says to Do Next
-
Will Micron Be a Trillion-Dollar Company By 2030?
-
Crypto Languishes As Oil Prices Soar
-
Wells Fargo CEO drops 3-word warning on economy
-
OpenAI COO Shifts Out of Role, AGI CEO Taking Medical Leave
-
2 Top Oversold Tech Stocks to Buy Before They Soar
-
SpaceX Is Worth $2 Trillion? What That Might Mean.
-
Trump’s Claims of Victory Clash With Iran War’s Gritty Reality
-
Life and Death Aboard Ships Stranded Near the Strait of Hormuz
-
Striking Beef Plant Workers to Resume Work
-
Morning Brief: Hope for Hormuz lifts markets
-
Nvidia Still Looks Cheap – Shorting Out-of-the-Money NVDA Put Options Is Attractive
-
Trade Strait of Hormuz Headlines and Profit with Unusual Options Activity in Royal Caribbean Stock
-
TSMC (TSM) to Launch 3nm Wafer Production at Second Japan Factory in 2028
-
Broadcom (AVGO) and Carahsoft Announce $970M BPA with DISA
-
Eli Lilly (LLY) Receives FDA Approval for Foundayo Weight Management Pill
-
Palantir (PLTR) Announces 5-Year Partnership Expansion with Stellantis
-
Intel (INTC) to Repurchase 49% Interest in Fab 34 JV for $14.2B
-
Takeda (TAK) Receives FDA Priority Review for Rusfertide in PV Treatment
2026-02-05



































